SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
EU and US crisis concept as a Broken Rope stretched with force and stressed to a decoupling metaphor for pressure on the economic and political relationship between Brussels and Washington.
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with Trump’s Most Favored Nation policy, patients will suffer.
April 2, 2026
 · 
3 min read
 · 
Annalee Armstrong
Hands protect to stop rectangle block dominos with others rectangle standing. Risk and crisis management concept.
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.
April 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
In this episode of Denatured, you’ll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech’s next big frontier.
April 2, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Hand drawing of a light bulb from a ball of yarn, illustrating problem solving
Job Trends
Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges
Drug discovery can be an uphill battle, especially lately given recent upheaval at the FDA and muted investment activity. BioSpace spoke to four industry executives about key issues facing those working in this space, starting with planning around uncertainty.
April 2, 2026
 · 
5 min read
 · 
Angela Gabriel
Novo Nordisk advertising flags and logo on facade
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
As Novo Nordisk cuts 400 jobs at the troubled site, Scholar Rock has seen enough progress that it included the facility in a resubmission for FDA approval.
April 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
April 1, 2026
 · 
3 min read
 · 
Heather McKenzie
Illustration with handshake, rocket launch and sales chart
Business
11 Startups Selected for National Life Sciences Accelerator Program
Of the 11 companies participating in the spring cohorts of the Drive program run by MassBio and SCbio, eight have locations in Massachusetts. One cohort focuses on biotech and the other on biomarkers and diagnostics.
April 1, 2026
 · 
2 min read
 · 
Angela Gabriel
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Biogen, Eli Lilly, Merck and Novartis spent more than $20 billion to absorb biotechs with promising or approved drugs; the rare disease space notched approvals for therapies from Denali Therapeutics, Rocket Pharmaceuticals and Biogen; and Wave’s stock lost half its value after its RNA-based obesity candidate failed to impress investors.
April 1, 2026
 · 
1 min read
 · 
Heather McKenzie
Money dollar rolled up with pills flowing out isolated on blue background, high costs of expensive medication concept. Copy space.
Funding
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.
April 1, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS